| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $1.7M | -60.8% | -54.8% |
| SG&A Expense | $3.8M | +47.8% | +62.2% |
| Operating Income | -$5.5M | +20.1% | +9.5% |
| Net Income | -$5.6M | +18.2% | +4.5% |
| EPS (Basic) | -$0.21 | +25.0% | +22.2% |
| EPS (Diluted) | -$0.21 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.0M | -29.3% | -77.1% |
| Current Assets | $5.2M | -21.6% | -72.3% |
| Total Assets | $53.7M | -6.6% | -48.5% |
| Current Liabilities | $5.7M | -25.3% | +1.5% |
| Total Liabilities | $7.5M | -20.6% | -16.3% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$16.1M | — | — |
| Financing Cash Flow | $7.3M | — | — |
| +22.2% |
| $46.2M |
| -3.8% |
| -51.5% |